BLLN vs GRAL vs NTRA Stock Comparison

BillionToOne, Grail and Natera Prices as of Nov 13, 2026 Peers: Industry group
BLLN BillionToOne, Inc.
$105.15 +7.4% 1M +17.4% 1Y
Market cap
$4.60B
P/E
100.1x
Revenue (TTM)
$436.87M
Div. yield
–
Diagnostic Labs Healthcare
5 wins
GRAL GRAIL, Inc.
$115.89 -17.0% 1M +39.3% 1Y
Market cap
$4.98B
P/E
–
Revenue (TTM)
$66.30M
Div. yield
–
Diagnostic Labs Healthcare
NTRA Natera, Inc.
$319.09 -19.2% 1M +59.0% 1Y
Market cap
$41.80B
P/E
–
Revenue (TTM)
$2.91B
Div. yield
–
Diagnostic Labs Healthcare
3 wins

Head to Head

8 decided of 12

BillionToOne leads on 5 of the 12 questions below (BillionToOne 5, Natera 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionBLLNGRALNTRALeader
Larger companyMarket capitalisation $4.60B $4.98B $41.80B NTRA
Cheaper on earningsLower P/E, profitable companies only 100.1x -12.3x -253.7x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 114.3x — — –
Faster revenue growthRevenue growth, trailing twelve months +71.9% +12.3% +37.4% BLLN
More profitableNet margin, trailing twelve months 10.5% -255.1% -5.7% BLLN
Better return on capitalReturn on invested capital 6.9% — -9.9% BLLN
Less leveragedLower net debt / EBITDA -9.1x — 5.6x BLLN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +17.4% +39.3% +59.0% NTRA
Better 5-year returnAnnualised price return, 5 years — — +22.7%/yr –
Less volatileAnnualised volatility, 1 year 91.9% 112.9% 52.1% NTRA
Higher overall scoreMean of the five percentile scores vs peers 58/100 38/100 52/100 BLLN

Percentile Scorecard

BLLNGRALNTRA

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisBLLNGRALNTRA
Valuation 22 #77 of 99 5 #94 of 99 13 #86 of 99
Growth 100 #1 of 89 42 #52 of 89 80 #19 of 89
Profitability 63 #35 of 92 6 #87 of 92 35 #60 of 92
Financial Health 96 #5 of 103 100 #1 of 103 85 #16 of 103
Shareholder Returns 7 #59 of 63 – 45 #35 of 63
Overall 58 38 52
  • BLLN ranked among 103 companies in Healthcare Providers
  • GRAL ranked among 103 companies in Healthcare Providers
  • NTRA ranked among 103 companies in Healthcare Providers

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodBLLNGRALNTRASPY
1 month +7.4%-17.0%-19.2% -2.0%
3 months +12.7%+70.8%+3.0% -2.8%
6 months +27.3%+94.3%+71.2% +2.0%
Year to date +28.5%+35.4%+39.3% +10.6%
1 year +17.4%+39.3%+59.0% +12.2%
3 years ——+512.2% +68.1%
3 years, per year ——+83.0% +18.9%
5 years ——+177.4% +61.4%
5 years, per year ——+22.7% +10.1%
10 years ——+2,761.8% +248.5%
10 years, per year ——+39.9% +13.3%

Risk

MeasureBLLNGRALNTRASPY
Volatility, 1Y 91.9%112.9%52.1% 13.6%
Downside volatility, 1Y 104.0%129.8%53.1% 13.9%
Beta vs S&P 500, 1Y 1.362.901.29 1.00
Return / volatility, 1Y 0.190.351.13 0.90
Max drawdown, 5Y -50.8%-62.9%-75.7% -25.4%
From 52-week high -29.9%-27.1%-26.8% -3.2%
52-week high $149.97$158.92$436.00 $779.14
52-week low $64.03$43.03$182.65 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleBLLNGRALNTRA
P/E now vs peer median 108.2xmedian 22.4x -13.3xmedian 22.4x -279.0xmedian 22.4x
P/S now vs peer median 11.5xmedian 1.3x 32.6xmedian 1.3x 15.8xmedian 1.3x
EV/EBITDA now vs peer median 87.4xmedian 14.2x -9.8xmedian 14.2x -248.1xmedian 14.2x
P/FCF now vs peer median 147.7xmedian 19.0x -16.6xmedian 19.0x 877.9xmedian 19.0x
P/B now vs peer median 8.8xmedian 2.6x 2.1xmedian 2.6x 24.6xmedian 2.6x
PEG now vs peer median —median 0.84 —median 0.84 -7.78median 0.84

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsBLLNGRALNTRA
Revenue $436.87M $66.30M $2.91B
Gross profit $311.95M $75.17M $1.84B
Operating income $44.69M -$578.58M -$260.42M
Net income $49.39M -$406.18M -$164.72M
Free cash flow $33.91M -$312.00M $52.47M
R&D $66.47M $188.17M $856.40M
EPS (diluted) $0.86 $-8.68 $-1.14
Cash & equivalents $561.51M $29.00M $1.10B
Total debt $89.00M – $80.30M
Shares (diluted) 53.73M 46.78M 144.07M
Enterprise value $2.46B $1.60B $37.42B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricBLLNGRALNTRA
P/E 108.2x -13.3x -279.0x
P/FCF 147.7x -16.6x 877.9x
P/Operating cash flow 104.5x -16.9x 216.5x
P/S 11.5x 32.6x 15.8x
P/B 8.8x 2.1x 24.6x
P/Tangible book 8.8x 7.3x 30.4x
EV/EBITDA 87.4x -9.8x -248.1x
EV/EBIT 101.5x -7.6x -173.0x
EV/Revenue 10.4x 27.6x 15.5x
EV/FCF 133.8x -14.1x 858.4x
EV/Operating cash flow 94.7x -14.4x 211.7x
PEG (3Y EPS CAGR) – – -7.78

Growth

14 metrics
MetricBLLNGRALNTRA
Revenue growth (1Y) 71.9% 12.3% 37.4%
Revenue CAGR (3Y) – – 43.3%
Gross profit growth (1Y) 88.4% 13.1% 41.1%
Gross profit CAGR (3Y) – – 68.2%
Operating income growth (1Y) 844.7% -0.7% 26.0%
Operating income CAGR (3Y) – – 19.7%
Net income growth (1Y) 593.9% 0.0% 46.7%
Net income CAGR (3Y) – – 30.9%
EPS growth (1Y) 193.7% 22.8% 49.3%
EPS CAGR (3Y) – – 35.9%
Operating cash flow growth (1Y) 794.7% 6.8% 9.5%
Operating cash flow CAGR (3Y) – – 40.7%
Free cash flow growth (1Y) 934.5% 5.4% -50.5%
Free cash flow CAGR (3Y) – – 29.4%

Profitability

14 metrics
MetricBLLNGRALNTRA
Gross margin 71.4% 47.2% 63.3%
EBITDA margin 11.9% -282.4% -6.2%
Operating margin 10.2% -363.4% -9.0%
Pretax margin 11.4% -344.3% -7.7%
Net margin 10.5% -255.1% -5.7%
FCF margin 7.8% -196.0% 1.8%
Operating cash flow margin 11.0% -192.4% 7.3%
Return on equity 9.0% -16.3% -8.9%
Return on assets 6.6% -14.6% -6.1%
Return on invested capital 6.9% – -9.9%
Return on capital employed 6.5% -21.5% -12.5%
Asset turnover 0.6x 0.1x 1.1x
Cash conversion (OCF / net income) 1.0x 0.8x -1.3x
Stock comp / revenue 7.0% 40.3% 13.6%

Financial Health

11 metrics
MetricBLLNGRALNTRA
Debt / assets 11.7% – 2.9%
Debt / equity 0.2x – 0.0x
Net debt / EBITDA -9.1x – 5.6x
Debt / FCF 2.6x – 1.5x
Liabilities / assets 25.5% 10.1% 32.0%
Equity / assets 74.5% 89.9% 68.0%
Interest coverage 1,655x – -70.8x
Current ratio 11.2x 8.9x 2.8x
Quick ratio 10.7x 8.6x 2.6x
Cash ratio 9.3x 8.4x 1.8x
Altman Z-score 16.82 5.53 31.15

Shareholder Returns

7 metrics
MetricBLLNGRALNTRA
Dividend yield – – –
Net buyback yield -6.1% – -0.1%
Shareholder yield -6.1% – -0.1%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusBLLNGRALNTRA
Forward P/E 114.3xFY2026 – –
EPS, next fiscal year $0.92FY2026 $-9.16FY2026 $-1.62FY2026
EPS growth, next FY +557.1%FY2026 – –
EPS growth, the year after -2.2% – –
Revenue, next fiscal year $484.85MFY2026 $158.71MFY2026 $3.16BFY2026
Revenue growth, next FY +58.9%FY2026 +7.8%FY2026 +36.9%FY2026
Revenue growth, the year after +27.2% +37.5% +7.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersBLLNGRALNTRA
Held by institutions 32.6% 85.4% 95.5%
Institutions holding 155 374 850
Change in shares held, QoQ +34.7% +8.4% +2.7%
Institutions buying 127 183 515
Institutions selling 13 101 240
Buyers to sellers 9.77 1.81 2.15

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

BLLNGRALNTRA
BLLN 1.00 0.35 0.32
GRAL 0.35 1.00 0.43
NTRA 0.32 0.43 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, BLLN, GRAL and NTRA?

Natera (NTRA) is the largest by market capitalisation: BillionToOne (BLLN) $4.60B, Grail (GRAL) $4.98B, Natera (NTRA) $41.80B.

Which company is growing faster?

BillionToOne (BLLN) grew revenue fastest over the trailing twelve months: BillionToOne (BLLN) +71.9%, Grail (GRAL) +12.3%, Natera (NTRA) +37.4%.

Which company is more profitable?

BillionToOne (BLLN) has the highest net margin (BillionToOne (BLLN) 10.5%, Grail (GRAL) -255.1%, Natera (NTRA) -5.7%). On return on invested capital, BillionToOne (BLLN) leads (BillionToOne (BLLN) 6.9%, Natera (NTRA) -9.9%).

Which stock has performed better?

Over the past year Natera (NTRA) returned the most: BillionToOne (BLLN) +17.4%, Grail (GRAL) +39.3%, Natera (NTRA) +59.0%. Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Natera (NTRA) has been the steadiest (BillionToOne (BLLN) 91.9%, Grail (GRAL) 112.9%, Natera (NTRA) 52.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, BLLN, GRAL and NTRA?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, BillionToOne (BLLN) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.